Calithera Biosciences, Inc. (CALA)

Calithera Biosciences, Inc. (CALA) Healthcare & Pipeline Overview

Calithera Biosciences is pioneering novel cancer therapies by targeting tumor metabolism and immunology, offering a unique approach in a competitive landscape. With a focused pipeline and strategic collaborations, Calithera aims to deliver innovative solutions in oncology, despite its current market capitalization of $0.00B.

Investment Thesis

Calithera Biosciences presents a notable research candidate for those seeking exposure to innovative cancer therapies. The company's focus on tumor metabolism and immunology targets a critical area in oncology, with potential for significant breakthroughs. Key value drivers include the advancement of INCB001158 through Phase 1/2 clinical trials and the development of CB-280 for cystic fibrosis. Strategic collaborations with Pfizer and Incyte further validate Calithera's approach and provide potential revenue streams. While the company's market cap is currently $0.00B, successful clinical trial outcomes and commercialization of its pipeline could drive substantial growth. The negative beta of -3.29 suggests the stock may move inversely to the market. Investors may want to evaluate the inherent risks of clinical-stage biopharmaceutical companies, but the potential rewards could be substantial.

Based on FMP financials and quantitative analysis

Key Highlights

• Calithera Biosciences focuses on developing small molecule compounds for tumor metabolism and tumor immunology targets.
• INCB001158, an orally bioavailable arginase inhibitor, is in Phase 1/2 clinical trial for hematology and oncology.
• Collaboration with Pfizer to evaluate talazoparib and palbociclib in combination with telaglenasta.
• License agreement with Incyte Corporation for the research, development, and commercialization of INCB001158.
• Market capitalization is $0.00B, reflecting the early stage of the company's development.

Competitors & Peers

Strengths

• Novel approach to cancer treatment by targeting tumor metabolism and immunology.
• Strategic collaborations with Pfizer, Incyte, and Antengene.
• Pipeline of small molecule compounds in various stages of development.
• Focus on unmet needs in oncology and cystic fibrosis.

Weaknesses

• Clinical-stage company with no currently marketed products.
• Reliance on clinical trial outcomes for future growth.
• Limited financial resources.
• Small number of employees (8).

Catalysts

• Upcoming: Clinical trial results for INCB001158 in hematology and oncology.
• Upcoming: Clinical trial results for CB-280 in cystic fibrosis.
• Ongoing: Progress in collaboration with Pfizer on combination therapies.
• Ongoing: Development and commercialization of CB-708 by Antengene.
• Ongoing: Advancement of ATG-037 through clinical trials.

Risks

• Potential: Clinical trial failures could significantly impact the company's value.
• Potential: Regulatory hurdles and delays could delay or prevent commercialization.
• Ongoing: Competition from larger pharmaceutical companies with greater resources.
• Potential: Patent challenges and intellectual property disputes could impact the company's competitive position.
• Ongoing: Limited financial resources could constrain the company's ability to advance its pipeline.

Growth Opportunities

• Advancement of INCB001158: The successful progression of INCB001158 through Phase 1/2 clinical trials for hematology and oncology represents a significant growth opportunity. Positive clinical data could lead to further development and potential commercialization, addressing a substantial market in cancer therapy. The timeline for this growth opportunity is dependent on clinical trial outcomes, with potential for initial results within the next 1-2 years. Calithera's competitive advantage lies in its focus on arginase inhibition, a novel approach to cancer treatment.
• Development of CB-280 for Cystic Fibrosis: The development of CB-280, an oral arginase inhibitor, for the treatment of cystic fibrosis and chronic airway infection presents another growth avenue. Successful completion of clinical trials and subsequent commercialization could address a significant unmet need in this patient population. The timeline for this growth opportunity is contingent on clinical trial results, with potential for advancement in the next 2-3 years. Calithera's competitive advantage lies in its expertise in arginase inhibition and its potential to develop a novel therapy for cystic fibrosis.
• Expansion of Collaboration with Pfizer: The clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib in combination with telaglenasta offers a growth opportunity through potential combination therapies. Positive results from these trials could lead to new treatment options and revenue streams for Calithera. The timeline for this growth opportunity depends on the progress of the clinical trials, with potential for results within the next 1-2 years. Calithera's competitive advantage is its ability to collaborate with a major pharmaceutical company like Pfizer.
• Commercialization of CB-708: The license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708 presents a growth opportunity through potential revenue from milestones and royalties. Successful development and commercialization of CB-708 by Antengene could generate significant financial returns for Calithera. The timeline for this growth opportunity depends on Antengene's progress, with potential for revenue generation in the next 3-5 years. Calithera's competitive advantage is its ability to out-license its assets to other companies.
• Development of ATG-037: ATG-037, an orally-bioavailable small molecule inhibitor of CD73, represents a growth opportunity through its potential to address unmet needs in cancer treatment. Successful development and commercialization of ATG-037 could generate significant revenue for Calithera. The timeline for this growth opportunity is dependent on clinical trial outcomes, with potential for advancement in the next 2-3 years. Calithera's competitive advantage lies in its focus on CD73 inhibition, a novel approach to cancer treatment.

Opportunities

• Successful clinical trial results leading to regulatory approval and commercialization.
• Expansion of collaborations with pharmaceutical companies.
• Development of new small molecule compounds targeting tumor metabolism and immunology.
• Potential for breakthrough therapies in oncology and cystic fibrosis.

Threats

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from larger pharmaceutical companies.
• Patent challenges and intellectual property disputes.

Competitive Advantages

• Proprietary small molecule compounds targeting tumor metabolism and immunology.
• Strategic collaborations with major pharmaceutical companies.
• Focus on novel targets like arginase, CD73, and IL4I1.

About CALA

Calithera Biosciences, Inc., founded in 2010 and headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company dedicated to discovering and developing small molecule compounds for cancer treatment. The company's focus lies in tumor metabolism and tumor immunology, aiming to create novel therapies that address unmet needs in oncology. Calithera's pipeline includes INCB001158, an orally bioavailable arginase inhibitor in Phase 1/2 clinical trials for hematology and oncology. They are also developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for cystic fibrosis and chronic airway infection. Additionally, Calithera is advancing ATG-037, an orally-bioavailable small molecule inhibitor of CD73, and CB-668, an orally administered inhibitor of the enzyme IL4I1. Calithera has established strategic collaborations to expand its research and development efforts. These include a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for human healthcare and a clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib in combination with telaglenasta. Furthermore, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158 and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. With a team of 8 employees, Calithera is focused on advancing its pipeline and delivering innovative cancer therapies.

What They Do

• Develop small molecule compounds for cancer treatment.
• Target tumor metabolism and tumor immunology.
• Offer INCB001158, an arginase inhibitor in Phase 1/2 clinical trial.
• Develop CB-280, an oral arginase inhibitor for cystic fibrosis.
• Develop ATG-037, an inhibitor of CD73.
• Develop CB-668, an inhibitor of the enzyme IL4I1.
• Collaborate with Pfizer on combination therapies.
• Partner with Incyte and Antengene for drug development.

Business Model

• Develop and license small molecule compounds.
• Collaborate with pharmaceutical companies on clinical trials.
• Generate revenue through licensing agreements and royalties.

Industry Context

Calithera Biosciences operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like Calithera are focused on developing novel therapies that address unmet needs in oncology. The company's focus on tumor metabolism and immunology positions it within a growing area of cancer research. Calithera faces competition from larger pharmaceutical companies and other biotechnology firms developing similar therapies.

Key Customers

• Patients with cancer.
• Patients with cystic fibrosis.
• Pharmaceutical companies through collaborations and licensing.

Financials

Chart & Info

Latest News

Analyst Consensus

MoonshotScore

Calithera Biosciences, Inc. Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Popular Stocks